GLAXOSMITHKLINE PLC Form 6-K October 14, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 14 October 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Sir Andrew Witty

b) Position/status Chief Executive Officer

Initial notification/

Initial notification amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

**Acquisition of Ordinary** Shares following the re-investment of dividends

paid to shareholders on 13 October 2016, on shares held

through the Company's ShareReward Plan.

Price(s) and Price(s) Volume(s)

volume(s) £17.0491 38

n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange f)

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr R G Connor a) Name President, Global

b) Position/status Manufacturing & Supply

Initial notification/ Initial notification c)

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held

through the Company's ShareReward Plan.

Price(s) and Price(s) Volume(s)

volume(s) £17.0491 47

n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

c) Initial notification/ Initial notification

c) amendment Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

 $3. \ \ instrument; (ii) \ each \ type \ of \ transaction; (iii) \ each \ date; \ and \ (iv) \ each$ 

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary

Shares following the re-investment of dividends paid to shareholders on 13

October 2016, on shares held through the Company's ShareReward Plan.

c) Price(s) and volume(s)

Price(s)

Volume(s)

£17.0491

15

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction

2016-10-13

Place of the transaction

London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position/status SVP, Global Ethics &

Compliance

Initial notification/

amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13

b) Nature of the transaction October 2016, on shares held

through the Company's ShareReward Plan.

Price(s) and Price(s) Volume(s)

volume(s) £17.0491 5

d) Aggregated information n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr S A Hussain a) Name

President, Global b) Position/status Pharmaceuticals

Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction 2.

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends

paid to shareholders on 13

October 2016, on shares held through the Company's

ShareReward Plan.

Price(s) and Price(s) Volume(s)

volume(s) £17.0491

n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's

ShareReward Plan.

Price(s) and Price(s) Volume(s) volume(s) £17.0491 53

n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

SVP, Human Resources b) Position/status

Initial notification/ Initial notification c)

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the

re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's ShareReward Plan.

Price(s) and Price(s) Volume(s)

volume(s) £17.0491 53

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status

SVP, Communications & Government Affairs

Initial notification/

c) Initial notification amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary Shares following the

re-investment of dividends

paid to shareholders on 13 October 2016, on shares held

through the Company's

ShareReward Plan.

Price(s) and Price(s) Volume(s)

volume(s) £17.0491 28

d) Aggregated information n/a (single transaction)

Aggregated volume Price

b) Nature of the transaction

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance

b) Position/status President, Pharmaceuticals

R&D

c) Initial notification/

Initial notification

amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

 $3. \ \ instrument; (ii) \ each \ type \ of \ transaction; (iii) \ each \ date; \ and \ (iv) \ each$ 

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares following the re-investment of dividends

paid to shareholders on 13 October 2016, on shares held

through the Company's

ShareReward Plan.

Price(s) and Price(s) Volume(s) volume(s) £17.0491 31

n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status CEO Designate

Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 b) Nature of the transaction October 2016, on shares held through the Company's ShareReward Plan. Price(s) and Price(s) Volume(s) volume(s) £17.0491 10 n/a (single transaction) Aggregated information d) Aggregated volume Price e) Date of the transaction 2016-10-13 Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mrs V A Whyte b) Position/status Company Secretary Initial notification/ c) Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882

**Acquisition of Ordinary** Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on shares held through the Company's

Price(s) and Price(s) Volume(s) volume(s) £17.0491 37

ShareReward Plan.

n/a (single transaction)

Aggregated information

b) Nature of the transaction

d)

Aggregated volume Price

e) Date of the transaction 2016-10-13

Place of the transaction London Stock Exchange

(XLON)

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: October 14, 2016

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc